<DOC>
	<DOCNO>NCT00419146</DOCNO>
	<brief_summary>The purpose trial study effect add omega-3 fatty acid EPA and/or Vitamins E + C antipsychotic drug young patient schizophrenia related psychosis .</brief_summary>
	<brief_title>Treatment Schizophrenia With Omega-3 Fatty Acid ( EPA ) Antioxidants</brief_title>
	<detailed_description>Objective : Study effect add Ethyl-EPA and/or Vitamins E + C antipsychotic drug young patient schizophrenia related psychosis . Methods material : - Design : Multicentre , randomize , double-blind , placebo-controlled , fix dose , 2x2 factorial , add-on clinical trial . - Sample : - Patients schizophrenia , schizoaffective disorder schizophreniform disorder ( DSM-IV ) ; age 18-40 year ; le 15 year since first psychotic symptom ; admit psychiatric department within previous 21 day screen ; speaks fluently Scandinavian language ; treat antipsychotic ; write informed consent ; know allergy trial agent ; substance dependence ( DSM-IV ) ; warfarin currently anamnestic indicator impair haemostasis . Planned : 200 patient . Actually include : 99 intent-to-treat patient . - Healthy control : age 18-40 year ; mental disorder ( DSM-IV ) . Included : 20 person . - Clinical assessment : Positive Negative Syndrome Scale ( PANSS ) ( main outcome variable ) . Self-report questionnaire . Adverse effect ( UKURS ) . Neurocognitive assessment battery . Niacin skin flush test . General medical assessment . - Blood sample : RBC fatty acid , S-Î±-tocopherol , F2-isoprostane ( kit ) , monocyte mRNA Phospholipase A22 ( PLA2 ) Gr4a 6a ( RT-PCR method ) , RBC Gr4a PLA2 concentration ( ELISA technique ) , range biochemical test . - Experimental treatment 16 week : Ethyl-EPA 2 g/d Placebo EPA Vitamin E 364 mg/d + Vitamin C 1000 mg/d Placebo Antioxidants - Statistics : Linear Mixed Model longitudinal analysis effect ; uni- multivariate method ( SPSS 12.0 - PASW Statistics 18 ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ascorbic Acid</mesh_term>
	<mesh_term>Tocopherols</mesh_term>
	<mesh_term>Vitamin E</mesh_term>
	<mesh_term>Tocotrienols</mesh_term>
	<mesh_term>alpha-Tocopherol</mesh_term>
	<mesh_term>Antioxidants</mesh_term>
	<criteria>Patients schizophrenia , schizophreniform disorder schizoaffective disorder ( DSMIV ) Admitted psychiatric hospital/department within previous twentyone day screen Less fifteen year , retrospect , since first psychotic symptom ( DSMIV 295 , criterion A,14 ) Age 1840 year Speaks fluently Scandinavian language A write informed consent must obtain trialrelated activity A diagnosis substance dependence ( DSMIV ) Known allergy study medication Currently take warfarin anamnestic indicator impair haemostasis ( profuse bleeding , except epistaxis )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophreniform disorder</keyword>
	<keyword>Schizoaffective disorder</keyword>
	<keyword>Psychotic disorder</keyword>
	<keyword>Randomized Controlled Trials</keyword>
	<keyword>Longitudinal Studies</keyword>
	<keyword>Fatty Acids , Omega-3</keyword>
	<keyword>Eicosapentaenoic Acid</keyword>
	<keyword>Vitamins</keyword>
	<keyword>Antioxidants</keyword>
	<keyword>Ascorbic Acid</keyword>
	<keyword>Alpha-Tocopherol</keyword>
	<keyword>Placebos</keyword>
	<keyword>Antipsychotic Agents</keyword>
	<keyword>Oxidative Stress</keyword>
	<keyword>Fatty Acids , Unsaturated</keyword>
	<keyword>Phospholipases</keyword>
	<keyword>Niacin</keyword>
	<keyword>Adverse effect</keyword>
	<keyword>Delusions</keyword>
	<keyword>Hallucinations</keyword>
	<keyword>Neuropsychological Tests</keyword>
	<keyword>Attention</keyword>
	<keyword>Memory</keyword>
	<keyword>Hypertriglyceridemia</keyword>
	<keyword>Models , Statistical</keyword>
</DOC>